<p>近期制药行业中较受欢迎的股票之一在周二遭到了投资者的冷遇。<strong>礼来</strong>(LLY -5.50%) 今天的交易收盘时价值下跌近 6%，这明显逊色于基准 <strong>标准普尔 500</strong> 指数的 0.3% 的跌幅。不过，这一下降并不完全是礼来的错。</p>
<h2>减重，降低指引</h2>
<p>礼来最近的受欢迎程度在很大程度上归功于其进入了利润丰厚的减肥药市场。在 2023 年底，其 Zepbound——本质上与其糖尿病药物 Mounjaro 相同的治疗——获得了治疗肥胖的批准，公司因此迅速发展。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<p>然而在周二，该领域的标杆 <strong>诺和诺德</strong> 却遭遇了大跌。今天早上，该公司下调了全年销售和营业利润的指引。</p>
<p>前者的增长预测被下调至 2024 年 8% 至 14%（之前的指引范围为 13% 至 21%）。营业利润的预期也相同，现在预计增长范围为 10% 至 16%。如果不是因为管理层之前的预测为 16% 至 24%，这将是令人鼓舞的。</p>
<p>诺和诺德以开发和销售 Wegovy 而闻名，这是美国食品药品监督管理局专门批准用于减肥的首个 GLP-1 药物。该公司凭借这一药物飞速崛起并赢得了赞誉，而这仍然是其关键产品。投资者可能担心礼来的 Zepbound 也会表现不如预期。</p>
<h2>不是紧急情况</h2>
<p>我认为没有人应该因为这个（或诺和诺德）而对礼来按下恐慌按钮。对肥胖药物的需求依然强劲且几乎没有限制，因此 Zepbound 和 Wegovy——至少目前仍受益于缺乏竞争对手——应该继续成为增长驱动力。</p>
<p>此外，就礼来而言，这家庞大的制药公司拥有广泛的产品组合和非常广泛的开发管道，因此它并不依赖于一种药物——无论该药物目前有多受欢迎。</p>

礼来

<p>礼来的股票下跌近 6%，表现逊色于标准普尔 500 指数的 0.3% 下跌，主要是由于对其减肥药 Zepbound 表现的担忧，此前诺和诺德下调了销售和利润预期。尽管出现下滑，分析师认为肥胖药物的需求依然强劲，礼来的多元化产品组合降低了与任何单一产品相关的风险</p>

<p>One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. <strong>Eli Lilly</strong>(LLY -5.50%) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether <strong>S&amp;P 500</strong> index. That decline wasn't necessarily Eli Lilly's fault, though.</p>
<div class="lb-trans"><p>近期制药行业中较受欢迎的股票之一在周二遭到了投资者的冷遇。<strong>礼来</strong>(LLY -5.50%) 今天的交易收盘时价值下跌近 6%，这明显逊色于基准 <strong>标准普尔 500</strong> 指数的 0.3% 的跌幅。不过，这一下降并不完全是礼来的错。</p>
</div><h2>Reducing weight, reducing guidance</h2>
<div class="lb-trans"><h2>减重，降低指引</h2>
</div><p>Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races.</p>
<div class="lb-trans"><p>礼来最近的受欢迎程度在很大程度上归功于其进入了利润丰厚的减肥药市场。在 2023 年底，其 Zepbound——本质上与其糖尿病药物 Mounjaro 相同的治疗——获得了治疗肥胖的批准，公司因此迅速发展。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F827123%2Fhealthcare-professional-inspecting-charts.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was <strong>Novo Nordisk</strong>, which this morning lowered its guidance for both full-year sales and operating profit.</p>
<div class="lb-trans"><p>然而在周二，该领域的标杆 <strong>诺和诺德</strong> 却遭遇了大跌。今天早上，该公司下调了全年销售和营业利润的指引。</p>
</div><p>The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%.</p>
<div class="lb-trans"><p>前者的增长预测被下调至 2024 年 8% 至 14%（之前的指引范围为 13% 至 21%）。营业利润的预期也相同，现在预计增长范围为 10% 至 16%。如果不是因为管理层之前的预测为 16% 至 24%，这将是令人鼓舞的。</p>
</div><p>Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected.</p>
<div class="lb-trans"><p>诺和诺德以开发和销售 Wegovy 而闻名，这是美国食品药品监督管理局专门批准用于减肥的首个 GLP-1 药物。该公司凭借这一药物飞速崛起并赢得了赞誉，而这仍然是其关键产品。投资者可能担心礼来的 Zepbound 也会表现不如预期。</p>
</div><h2>Not an emergency</h2>
<div class="lb-trans"><h2>不是紧急情况</h2>
</div><p>I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers.</p>
<div class="lb-trans"><p>我认为没有人应该因为这个（或诺和诺德）而对礼来按下恐慌按钮。对肥胖药物的需求依然强劲且几乎没有限制，因此 Zepbound 和 Wegovy——至少目前仍受益于缺乏竞争对手——应该继续成为增长驱动力。</p>
</div><p>Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be.</p>
<div class="lb-trans"><p>此外，就礼来而言，这家庞大的制药公司拥有广泛的产品组合和非常广泛的开发管道，因此它并不依赖于一种药物——无论该药物目前有多受欢迎。</p>
</div>

为什么礼来的股票今天表现不佳